Randomized, multicenter, double-blind, phase 3 trial of Tavocept versus Placebo in patients with newly diagnosed or relapsed advanced (stage IIIB/IV) primary adenocarcinoma of the lung treated with docetaxel or paclitaxel plus cisplatin.

Trial Profile

Randomized, multicenter, double-blind, phase 3 trial of Tavocept versus Placebo in patients with newly diagnosed or relapsed advanced (stage IIIB/IV) primary adenocarcinoma of the lung treated with docetaxel or paclitaxel plus cisplatin.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 16 May 2014

At a glance

  • Drugs Dimesna (Primary) ; Cisplatin; Docetaxel; Paclitaxel
  • Indications Lung cancer; Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors BioNumerik Pharmaceuticals
  • Most Recent Events

    • 16 May 2014 New source identified and integrated (ClinicalTrials.gov; NCT00966914).
    • 22 Apr 2013 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
    • 16 Nov 2011 Actual initiation date (21 Oct 2009) added as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top